Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Billionaire investor Ken Griffin is the founder of Citadel Advisors, one of the world’s most successful alternative ...

Discover the latest advancements in gene therapy for rare diseases like Friedreich's Ataxia and Duchenne Muscular Dystrophy, ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Neurocrine (NBIX – Research Report), with a price ...

Bain Capital is in talks to acquire Mitsubishi Chemical Group's pharmaceutical business in a potential multibillion-dollar deal, a person familiar with the matter said, a transaction that could ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...